St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease

St. Jude Medical initiates enrollment in FAME II trial for coronary artery disease
St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR that the first patient was enrolled in the FAME II (Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease) trial.

Read more on News-Medical-Net

More Meth Drug Addiction Info:

• Heart Attack Symptoms, Causes and Treatment: Small Lifestyle …
• A Woman?s Heart- Real Foes and Friends | Pharmacy Online Shop Blog
• Top Medical Device Companies in 2010 : Medical Sales Recruiter …
• AtriCure Announces June Investor Conference Schedule | Medical …
• When The FDA Comes Knocking, Is Your Company Prepared …
• Atherosclerosis Or Coronary Artery Disease (CAD) – Drug Pipeline …
• Australia Cardiovascular Devices Market Outlook to 2016 | Snipsly
• Data Presented at EuroPCR 2010 Demonstrate Effectiveness of …
• St. Jude Medical to evaluate cost-effectiveness of FFR for …
• For the First Time, at EuroPCR, InspireMD Will Provide a Sneak …